Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date

Figures & data

Figure 1 Netarsudil chemical structure depicting the free base and dimesylate to improve bioavailability.

Note: Reproduced with permission from Aerie Pharmaceuticals, Inc. Prescribing information for Rhopressa. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf.³³

Table 1 Efficacy results with netarsudil 0.02% daily dosing in clinical trials

Clinical triala	Sample size	Mean baseline IOP (mmHg)	Mean 3-month IOP (8 AM)	Noninferiority to timolol 0.5% twice daily?
ROCKET-1b	182	23.42	19.81	No
ROCKET-1c	113	22.39	18.22	Yes
ROCKET-2d	129	22.54	18.24	Yes

Notes:

a Serle, et al.¹⁸

b ROCKET-1, primary efficacy population with baseline IOP <27 mmHg.

c ROCKET-1, per-protocol population with post hoc end point and baseline IOP <25 mmHg.

d ROCKET-2, primary efficacy population with baseline IOP <25 mmHg.

Abbreviations: IOP, intraocular pressure; ROCKET-1, Rho Kinase Elevated IOP Treatment Trial 1; ROCKET-2, Rho Kinase Elevated IOP Treatment Trial 2.

Aerie Pharmaceuticals, IncPrescribing information for Rhopressa Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdfAccessed September 26, 2018

 Google Scholar

SerleJBKatzLJMcLaurinETwo phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)Am J Ophthalmol201818611612729199013

 PubMed Web of Science ®Google Scholar